Do fibrates lower heart risk?
Yes, modestly. Across 12 trials, major cardiovascular events occurred in 10.6% of people on fibrates and 13.7% of people on placebo, about 3 fewer events per 100 people treated. That is a 13% relative reduction. The benefit tracked with how much LDL cholesterol fell, not with triglyceride lowering.
Dr. Kumar’s Take:
This large review study looked at over 53,000 patients to see if fibrates, older cholesterol medications, offer heart protection. Fibrates have historically been used for lowering high triglycerides. In this review, they were linked to fewer heart attacks and related events overall, and the size of the benefit tracked with how much they lowered LDL cholesterol. The authors concluded the benefit appears to be attributable to LDL lowering. Changes in triglycerides showed no significant link to heart risk.
That does not make triglycerides irrelevant, but it suggests LDL lowering is where the heart benefit of fibrates comes from.
Key Takeaways:
- The heart benefit of fibrates tracked with how much LDL cholesterol fell: each 1 mmol/L drop was linked to a 29% lower risk.
- Triglyceride changes showed no significant link to heart attacks or strokes.
- The absolute benefit was modest: about 3.1% fewer events over the trials (NNT ~33). (I calculated these numbers from the event counts in the paper)
Brief Summary:
A meta-analysis of 12 randomized trials (totaling 53,231 patients) evaluated the impact of fibrate therapy on heart outcomes. The main goal was to see if fibrates reduced major adverse cardiovascular events (MACE), including heart attack, stroke, cardiovascular death, and need for heart procedures.
MACE occurred in 10.6% of patients on fibrates and 13.7% on placebo, an absolute risk reduction of about 3.1% over the course of the trials. The number needed to treat (NNT) to prevent one MACE was about 33 patients. In relative terms, fibrates showed a 13% relative risk reduction (RR 0.87, 95% CI 0.81 to 0.94). Importantly, the benefit was closely tied to how much LDL cholesterol dropped, not how much triglycerides dropped.
Study Design:
This was a meta-analysis of 12 randomized controlled trials published up to February 2023, including over 53,000 patients. The studies compared fibrate drugs (like gemfibrozil, fenofibrate, and others) to placebo, and tracked cardiovascular events.
Researchers also looked at how lipid levels changed with treatment. A special analysis (called meta-regression) was used to see if lowering LDL or triglycerides made a difference in outcomes.
Results:
- Major adverse cardiovascular events (MACE) occurred in 10.6% of patients on fibrates vs. 13.7% on placebo, an absolute risk reduction of about 3.1%.
- Relative risk of Major adverse cardiovascular events (MACE) was 0.87, meaning a 13% lower risk on fibrates.
- Number needed to treat (NNT) = about 33 patients over the course of the trials to prevent one MACE.
- Each 1 mmol/L drop in LDL-C was linked to a 29% lower risk of MACE
- Triglyceride reduction had no clear link to fewer events
Why Does LDL Matter More Than Triglycerides Here?
The researchers used a meta-regression to compare how much each trial lowered lipids with how much it cut events. Each 1 mmol/L drop in LDL cholesterol was linked to a 29% lower risk of major cardiovascular events. Triglyceride changes showed no significant link (RR 0.96 per 1 mmol/L drop, p = 0.86), though that does not prove triglyceride lowering has no effect.
This suggests fibrates help the heart mainly through their effect on LDL.
The weak link with triglyceride lowering challenges older thinking. It raises questions about whether triglycerides are a reliable target for reducing cardiovascular risk, at least with current medications.
Related Studies and Research
Red Yeast Rice and Metabolic Syndrome: Investigates how red yeast rice affects lipid levels and metabolic markers in people with metabolic syndrome.
Plant Sterols, Cholesterol, and Heart Health: Reviews how plant sterols impact cholesterol levels and their potential role in heart disease prevention.
Ezetimibe and Heart Disease: A Review: Examines how ezetimibe lowers LDL cholesterol and its effect on cardiovascular outcomes.
Fiber and Heart Disease Risk: Analyzes the role of dietary fiber in cardiovascular health and cholesterol reduction.
TG/HDL-C Ratio and Cardiovascular Risk: Explores the clinical importance of the triglyceride-to-HDL ratio in metabolic and cardiovascular risk.
LDL-C and Mortality: A Review: Investigates how LDL cholesterol levels correlate with mortality risk.
Frequently Asked Questions
Do fibrates help if I’m already on a statin?
The trials in this review compared fibrates with placebo, and the benefit tracked with how much LDL fell. Statins are a separate class of cholesterol drug, so whether adding a fibrate makes sense for you is a question for your doctor.
What are the main fibrates used?
Common ones include gemfibrozil, fenofibrate, bezafibrate, and pemafibrate. They are mostly used to lower triglycerides and modestly reduce LDL.
Are fibrates safe?
Generally yes, but side effects can include muscle pain, liver enzyme changes, and, rarely, kidney issues. Always discuss with your healthcare provider.
Should I take a fibrate to lower my triglycerides?
Lowering triglycerides might help with pancreatitis risk, especially if levels are very high. But for heart disease risk, lowering LDL seems more important.
Conclusion
Fibrates were linked to a modest drop in heart risk across 12 trials. Their benefit appears to come from lowering LDL, not from reducing triglycerides.
If you’re considering a fibrate, make sure it’s part of a larger plan that addresses LDL cholesterol, lifestyle, and other risk factors. The overall benefit is modest, but for the right person, it may still be meaningful.
